All In Biotech

Drug Trial Radar · NCT07665450

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator's Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Sep 4, 2030

Study completion Feb 2, 2035

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \[WBCs\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.

Conditions

  • Multiple Myeloma

Interventions

  • RamantamigDrug

    Ramantamig will be administered subcutaneously.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously or intravenously.

  • DexamethasoneDrug

    Dexamethasone will be administered orally or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 62 months
  2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)Time frame: Up to 12 months

Locations

103 sites in 14 countries. Site status is shown where the registry gives one.

  • St Vincent s Hospital Sydney

    Darlinghurst, Australia · Recruiting

  • Mater Hospital Brisbane

    South Brisbane, Australia · Recruiting

  • Fakultni nemocnice Brno

    Brno, Czechia · Recruiting

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia · Recruiting

  • Fakultni nemocnice Plzen

    Pilsen, Czechia · Recruiting

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Recruiting

  • Hopital Claude Huriez

    Lille, France · Recruiting

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, France · Recruiting

  • CHU Nantes

    Nantes, France · Recruiting

  • Aphp Hopital Saint Antoine

    Paris, France · Recruiting

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, France · Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, France · Recruiting

  • IUCT Oncopole Institut Claudius Regaud

    Toulouse, France · Recruiting

  • CHRU Tours Hopital Bretonneau

    Tours, France · Recruiting

  • CHU Nancy Brabois

    Vandœuvre-lès-Nancy, France · Recruiting

  • St. Barbara-Klinik Hamm GmbH

    Hamm, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg

    Würzburg, Germany · Recruiting

  • Uni General Hospital of Alexandroupolis

    Alexandroupoli, Greece · Recruiting

  • Evangelismos S A

    Athens, Greece · Recruiting

  • Laiko General Hospital of Athens

    Athens, Greece · Recruiting

  • Alexandra General Hospital of Athens

    Athens, Greece · Recruiting

  • Theageneio Cancer Hospital

    Thessaloniki, Greece · Recruiting

  • Geniko Nosokomeio Thessalonikis George Papanikolaou

    Thessaloniki, Greece · Recruiting

  • Rambam Med.Center - Hematology Institute

    Haifa, Israel · Recruiting

  • Carmel Medical Center

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Rabin Medical Center

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • A O U Sant Orsola Malpighi

    Bologna, Italy · Recruiting

  • S.C. Ematologia Azienda Ospedaliera S. Croce e Carle

    Cuneo, Italy · Recruiting

  • Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano

    Milan, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone

    Palermo, Italy · Recruiting

  • Catharina Ziekenhuis

    Eindhoven, Netherlands · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

  • Sint Antonius Ziekenhuis

    Nieuwegein, Netherlands · Recruiting

  • Zuyderland Medical Center

    Sittard-Geleen, Netherlands · Recruiting

  • UMCU

    Utrecht, Netherlands · Recruiting

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.